- Sona Nanotech’s (CSE: SONA) Targeted Hyperthermia Therapy (THT) will be assessed in a cancer research study
- The study will judge THT’s efficacy and ability to act as a catalyst in attenuating the development of colorectal, breast and melanoma tumor models and in facilitating systemic immune responses
- Sona’s gold nanorods via its THT, alongside precise immune modulation, aims to elevate immune activation and anti-tumor responses
- Sona Nanotech Inc. last traded at $0.19 per share
Sona Nanotech’s (CSE: SONA) Targeted Hyperthermia Therapy (THT) will be assessed in a cancer research study.
The study by the Giacomantonio Immuno-Oncology Research Group will judge THT’s efficacy and ability to act as a catalyst in attenuating the development of colorectal, breast and melanoma tumor models and in facilitating systemic immune responses.
Sona’s gold nanorods via its THT, alongside precise immune modulation, aims to elevate immune activation and anti-tumor responses.
The company and the research group have signed an agreement under which experiments will be conducted. The experiments will explore immune reprogramming by tumor antigen transfer as well as tumor response and immune modulation in subcutaneous tumor models after treatment with various immunotherapeutic interventions.
“This innovative study will go significantly beyond our current plans for THT applications to explore the potentially synergistic effect of its use with certain immunotherapy treatments for cancer,” Sona’s CEO, David Regan, said in a news release. “In it, we aim to harness the tremendous potential of immunotherapy, leveraging Sona’s biocompatible gold nanorods as a pivotal, catalytic element. This effort marks the beginning of Sona delivering on the ‘mountain of data’ we committed to developing in support of our planned regulatory submissions for human clinical trial approvals.”
Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The company researches and develops gold nanorod products. It makes products for diagnostic tests and medical treatment applications. The company’s product includes Gemini and saliva tests.
Sona Nanotech Inc. last traded at $0.19 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Sona Nanotech Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.